Radiofrequency ablation vs. hepatic resection for resectable colorectal liver metastases

Abstract

The treatments of resectable colorectal liver metastases (CRLM) are controversial. This study aimed to evaluate the relative efficacy and safety of hepatic resection (HR) and radiofrequency ablation (RFA) for treating resectable CRLM. Between January 2004 and May 2010, the enrolled patients were given hepatic resection (HR group; n=32) or percutaneous RFA (RFA group; n=21) as a first-line treatment for CRLM. All the tumors had a maximum diameter of 3.5 cm and all patients had five or less tumors. The patient background, tumor characteristics, cumulative survival rate and recurrence-free survival rate were assessed in both groups. There were significantly more patients with comorbidities in the RFA group than those in the HR group (17 in RFA group vs. 10 in HR group; P<0.000). The mean maximum tumor diameter in the HR group and RFA group was 2.25±0.68 and 1.89±0.62 cm (P=0.054), and the mean number of tumors was 2.28±1.05 and 2.38±1.12 (P=0.744), respectively. The 1-, 3- and 5-year cumulative survival rates in the HR group were 87.5%, 53.1% and 31.3%, respectively, and those in the RFA group were 85.7%, 38.1% and 14.2%, respectively with the differences being not significant between the two groups (P=0.062). The 1-, 3- and 5-year recurrence-free survival rates in the HR group were 90.6%, 56.3% and 28.1%, respectively, and those in the RFA group were 76.1%, 23.8% and 4.8%, respectively, with the differences being significant between the two groups (P=0.036). In conclusion, as HR has greater efficacy than RFA in the treatment of resectable CRLM, we recommend it as the first option for this malignancy.

Keywords

hepatectomy / hepatic resection / resectable colorectal liver metastases / radiofrequency ablation

References

[1] ZhangSW, LeiZL, LiGL, et al. . A report of cancer incidence and mortality from 34 cancer registries in China, 2006. China Cancer, 2010, 19(6): 356-365

[2] ChenWQ, ZhangSW, ZhengRS, et al. . A report of cancer incidence and mortality from 38 cancer registries in China, 2007. China Cancer, 2011, 20(3): 162-169

[3] ZhengRS, ZhangSW, WuLY, et al. . Report of incidence and mortality from Chinese registries in 2008. China Cancer, 2012, 21(1): 1-12

[4] McArdleCS, HoleDJ. Outcome following surgery for colorectal cancer. Br Med Bull, 2002, 64: 119-125 PMID: 12421729

[5] StanglR, Altendorf-HofmannA, CharnleyRM, et al. . Factors influencing the natural history of colorectal liver metastases. Lancet, 1994, 343(8910): 1405-1410 PMID: 7515134

[6] RautCP, IzzoF, MarraP, et al. . Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol, 2005, 12(8): 616-628 PMID: 15965731

[7] SutherlandLM, WilliamsJA, PadburyRT, et al. . Radiofrequency ablation of liver tumors: a systematic review. Arch Surg, 2006, 141(2): 181-190 PMID: 16490897

[8] GillamsAR. The use of radiofrequency in cancer. Br J Cancer, 2005, 92(10): 1825-1829 PMID: 15870717 PMCID: 2361772

[9] KubotaK, MakuuchiM, KusakaK, et al. . Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology, 1997, 26(5): 1176-1181 PMID: 9362359

[10] ImamuraH, SeyamaY, KokudoN, et al. . One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg, 2003, 138(11): 1198-1206 PMID: 14609867

[11] IidaH, AiharaT, IkutaS, et al. . Comparative study of percutaneous radiofrequency ablation and hepatic resection for small, poorly differentiated hepatocellular carcinomas. Hepatol Res, 2014, 44(10): E156-E162 PMID: 24164784

[12] AbdallaEK, VautheyJN, EllisLM, et al. . Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg, 2004, 239(6): 818-825 PMID: 15166961 PMCID: 1356290

[13] GleisnerAL, ChotiMA, AssumpcaoL, et al. . Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg, 2008, 143(12): 1204-1212 PMID: 19075173

[14] McKayA, DixonE, TaylorM. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg, 2006, 93(10): 1192-1201 PMID: 16983740

[15] SipersteinAE, BerberE, BallemN, et al. . Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg, 2007, 246(4): 559-565 PMID: 17893492

[16] WhiteRR, AvitalI, SofocleousCT, et al. . Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg, 2007, 11(3): 256-263 PMID: 17458595

[17] AloiaTA, VautheyJN, LoyerEM, et al. . Solitary colorectal liver metastasis: resection determines outcome. Arch Surg, 2006, 141(5): 460-466 PMID: 16702517

[18] MinamiY, KudoM. Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol, 2011, 2011: 104685 PMID: 21994847 PMCID: 3170722

[19] MinamiY, KudoM. Radiofrequency ablation of hepatocellular carcinoma: current status. World J Radiol, 2010, 2(11): 417-424 PMID: 21179308 PMCID: 3006479

[20] BuscariniE, SavoiaA, BrambillaG, et al. . Radiofrequency thermal ablation of liver tumors. Eur Radiol, 2005, 15(5): 884-894 PMID: 15754165

[21] TateishiR, ShiinaS, TerataniT, et al. . Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer, 2005, 103(6): 1201-1209 PMID: 15690326

[22] ChoiD, LimHK, RhimH, et al. . Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol, 2007, 14(8): 2319-2329 PMID: 17522947

[23] GoldbergSN, CharboneauJW, DoddGD, et al. . Image Guided Tumor ablation: proposal for standardization of terms and reporting criteria. Radiology, 2003, 228(2): 335-345 PMID: 12893895

[24] BerberE, HercegNL, CastoKJ, et al. . Laparoscopic radiofrequency ablation of hepatic tumors: prospective clinical evaluation of ablation size comparing two treatment algorithms. Surg Endosc, 2004, 18(3): 390-396 PMID: 14735342

[25] WengM, ZhangY, ZhouD, et al. . Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS One, 2012, 7(9): e45493 PMID: 23029051 PMCID: 3448670

[26] KoS, JoH, YunS, et al. . Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World J Gastroenterol, 2014, 20(2): 525-531 PMID: 24574721 PMCID: 3923027

[27] WongSL, ManguPB, ChotiMA, et al. . American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol, 2010, 20(28): 493-508

[28] FongY, FortnerJ, SunRL, et al. . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg, 1999, 230(3): 309-318 PMID: 10493478 PMCID: 1420876

[29] WeberSM, JarnaginWR, De MatteoRP, et al. . Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol, 2000, 7(9): 643-650 PMID: 11034240

[30] BakalakosEA, KimJA, YoungDC, et al. . Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg, 1998, 22(4): 399-404 PMID: 9523523

[31] GillamsAR, LeesWR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol, 2009, 19(5): 1206-1213 PMID: 19137310